Articles tagged with: PD 0332991
News»

The results of a Phase 1 trial suggest that the experimental drug PD 0332991 may be a safe and effective treatment for pre-treated multiple myeloma patients.
Dr. Ruben Niesvizky of the Weill Cornell Medical College, who presented the results at the American Society of Hematology (ASH) annual meeting in Orlando last month, pointed out that data about efficacy is limited at this point because it was a Phase 1 trial. However, he added “We are encouraged [by the results] because we have seen two very good partial responses.”
PD 0332991, which is …
News»

This Monday was the third full day of the American Society of Hematology 2010 annual meeting, and it was packed with multiple myeloma-related presentations. The Beacon published an update earlier today covering presentations made Monday morning. This article covers material from Monday afternoon and evening.
The first presentation of the afternoon was by Dr. Ruben Niesvizky of the Weill Cornell Medical College in New York. He reported on the results of a Phase 3 trial using Velcade (bortezomib)-based initial treatment (induction) regimens combined with weekly Velcade maintenance therapy (abstract).
Patients in this trial were newly …